Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy

The objective of this study was to assess the biologic activity of rosiglitazone, a peroxisome proliferator‐activated receptor γ agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change in prostate specific antigen (PSA) doubling time (PSADT) as the primary outcome variable.

[1]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[2]  J. Dekernion,et al.  Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.

[3]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[6]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[7]  G. Grunberger,et al.  Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.

[8]  T. Beer,et al.  High‐dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma , 2003, Cancer.

[9]  V. Weinberg,et al.  Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[11]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[12]  A. Renshaw,et al.  Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[14]  M. Moyad.  The placebo effect and randomized trials: analysis of conventional medicine. , 2002, The Urologic clinics of North America.

[15]  A. Pollack,et al.  Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  H. Koeffler.  Peroxisome proliferator-activated receptor γ and cancers , 2003 .

[17]  A A Tsiatis,et al.  Exact significance testing to establish treatment equivalence with ordered categorical data. , 1984, Biometrics.